Lung cancer survival study for adults receiving study treatment
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial is looking at how well a lung cancer treatment improves survival. It enrolls adults with confirmed lung cancer who can safely take the study medicines and have cancer that can be measured on scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re at least 18 years old.
- You have confirmed lung cancer from a biopsy or cell test.
- Your overall ability to do daily activities is limited only mildly (ECOG 0–2).
- Your expected survival is at least 12 weeks.
- Your scans show measurable tumors (lesions) that can be tracked.
- Your blood counts and major organ health (bone marrow, liver, kidneys, etc.) meet safety limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well immune checkpoint medicines (with or without chemotherapy) work for lung cancer, and looks for biomarkers—tests that may help predict who benefits. It may help you access a structured treatment plan and additional response testing.
This trial tests a personalized immune cell therapy for advanced or relapsed lung cancer. Doctors take your blood, create special T cells that target unique proteins on your cancer, and give them back to you to try to fight the tumor.
This study monitors how the heart and lungs respond to radiation therapy combined with immunotherapy for locally advanced lung cancer. It aims to learn how well patients tolerate treatment and to detect early signs of side effects.
This trial studies whether regularly reporting symptoms on a website helps predict (and possibly improve) outcomes for people with advanced lung cancer. It compares survival-related information using these web symptom reports alongside usual cancer treatment.
This study builds a detailed lung-cancer database by collecting clinical and lab information from people newly diagnosed. It aims to help doctors better understand lung cancer and how patients are treated from the start.
This trial studies how “before-surgery” (neoadjuvant) lung cancer treatments change the tumor environment by monitoring patients during care. It may help doctors better choose therapies and predict who benefits from treatment.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.